Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GT90001 and Nivolumab in Metastatic HCC
NCT03893695Phase 2Completed
- Sponsor
- Kintor Pharmaceutical Limited
- Start
- May 2019
- Primary completion
- May 2022
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ascrinvacumab in hepatocellular carcinoma (HCC), sponsored by Kintor Pharmaceutical Limited. Primary endpoint: Dose-limiting Toxicity at 28 days. Started May 2019; status: completed.
02
Drugs
ascrinvacumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03893695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03893695.